Intellia Therapeutics Inc (NASDAQ:NTLA) shares traded down 2.9% on Thursday . The stock traded as low as $22.20 and last traded at $22.49, with a volume of 77,737 shares. The stock had previously closed at $23.15.

Several research analysts have weighed in on the stock. Jefferies Group restated a “buy” rating on shares of Intellia Therapeutics in a research report on Wednesday. Leerink Swann assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 target price on the stock. Wedbush assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 target price on the stock. Zacks Investment Research lowered shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Finally, Credit Suisse Group AG assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $35.50.

The stock’s 50 day moving average is $19.10 and its 200 day moving average is $23.08. The firm’s market cap is $820.33 million.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.